13.03
price down icon2.76%   -0.37
after-market 시간 외 거래: 13.03
loading
전일 마감가:
$13.40
열려 있는:
$12.99
하루 거래량:
559.52K
Relative Volume:
1.31
시가총액:
$717.74M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-5.58%
1개월 성능:
-2.03%
6개월 성능:
-48.84%
1년 성능:
+0.00%
1일 변동 폭
Value
$12.52
$13.85
1주일 범위
Value
$12.52
$14.39
52주 변동 폭
Value
$11.10
$28.09

Bicara Therapeutics Inc Stock (BCAX) Company Profile

Name
명칭
Bicara Therapeutics Inc
Name
전화
617-785-8308
Name
주소
245 MAIN STREET, CAMBRIDGE
Name
직원
0
Name
트위터
Name
다음 수익 날짜
Name
최신 SEC 제출 서류
Name
BCAX's Discussions on Twitter

BCAX을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
BCAX
Bicara Therapeutics Inc
13.03 717.74M 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.82 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
634.23 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.87 36.10B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.02 35.03B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
272.17 28.24B 3.81B -644.79M -669.77M -6.24

Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-02-06 개시 Wedbush Outperform
2024-12-06 개시 H.C. Wainwright Buy
2024-11-05 개시 Rodman & Renshaw Buy
2024-10-08 개시 Cantor Fitzgerald Overweight
2024-10-08 개시 Morgan Stanley Overweight
2024-10-08 개시 Stifel Buy
2024-10-08 개시 TD Cowen Buy
모두보기

Bicara Therapeutics Inc 주식(BCAX)의 최신 뉴스

pulisher
08:59 AM

Cantor Fitzgerald maintains Overweight on Bicara Therapeutics stock - Investing.com

08:59 AM
pulisher
05:41 AM

Promising Data and Durable Responses Drive Buy Rating for Bicara Therapeutics - TipRanks

05:41 AM
pulisher
01:38 AM

Q1 EPS Estimate for Bicara Therapeutics Reduced by Analyst - Defense World

01:38 AM
pulisher
Mar 29, 2025

Bicara Therapeutics (NASDAQ:BCAX) Earns Outperform Rating from Wedbush - Defense World

Mar 29, 2025
pulisher
Mar 28, 2025

Charles Schwab Investment Management Inc. Takes Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World

Mar 28, 2025
pulisher
Mar 28, 2025

Stifel raises Bicara stock price target to $48, maintains Buy By Investing.com - Investing.com Canada

Mar 28, 2025
pulisher
Mar 28, 2025

Buy Rating for Bicara Therapeutics Inc. Driven by Promising Clinical Progress and Strong Financial Position - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

Bicara Therapeutics Reports Strong Financial Position and Clinical Progress - TipRanks

Mar 28, 2025
pulisher
Mar 27, 2025

Analysts Adjust Price Targets For Nkarta And Bicara - Evrim Ağacı

Mar 27, 2025
pulisher
Mar 27, 2025

Stifel raises Bicara stock price target to $48, maintains Buy - Investing.com India

Mar 27, 2025
pulisher
Mar 27, 2025

Bank of New York Mellon Corp Makes New Investment in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World

Mar 27, 2025
pulisher
Mar 27, 2025

Bicara Therapeutics Inc QTRLY Loss Per Share $0.39 - MarketScreener

Mar 27, 2025
pulisher
Mar 27, 2025

Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire

Mar 27, 2025
pulisher
Mar 27, 2025

Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides ... - Enid News & Eagle

Mar 27, 2025
pulisher
Mar 26, 2025

Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025 - GlobeNewswire

Mar 26, 2025
pulisher
Mar 18, 2025

Skandinaviska Enskilda Banken AB publ Purchases Shares of 38,035 Bicara Therapeutics Inc. (NASDAQ:BCAX) - MarketBeat

Mar 18, 2025
pulisher
Mar 15, 2025

Bicara Therapeutics Inc (BCAX): A New Perspective - Stocks Register

Mar 15, 2025
pulisher
Mar 15, 2025

Cantor Fitzgerald Reiterates “Overweight” Rating for Bicara Therapeutics (NASDAQ:BCAX) - Defense World

Mar 15, 2025
pulisher
Mar 14, 2025

Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives $41.20 Consensus Price Target from Analysts - Defense World

Mar 14, 2025
pulisher
Mar 13, 2025

Cantor Fitzgerald maintains Overweight on Bicara Therapeutics By Investing.com - Investing.com Canada

Mar 13, 2025
pulisher
Mar 13, 2025

Cantor Fitzgerald maintains Overweight on Bicara Therapeutics - Investing.com India

Mar 13, 2025
pulisher
Mar 12, 2025

Companies Like Bicara Therapeutics (NASDAQ:BCAX) Are In A Position To Invest In Growth - Yahoo Finance

Mar 12, 2025
pulisher
Mar 10, 2025

19,008 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Purchased by Rhumbline Advisers - Defense World

Mar 10, 2025
pulisher
Mar 05, 2025

Bicara Therapeutics Inc.’s (NASDAQ:BCAX) Lock-Up Period Set To Expire on March 12th - Defense World

Mar 05, 2025
pulisher
Feb 24, 2025

Bicara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference - The Manila Times

Feb 24, 2025
pulisher
Feb 21, 2025

Bicara Therapeutics (BCAX) Expected to Announce Quarterly Earnings on Tuesday - Defense World

Feb 21, 2025
pulisher
Feb 17, 2025

Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Rating of "Buy" from Analysts - MarketBeat

Feb 17, 2025
pulisher
Feb 17, 2025

Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives $41.20 Consensus PT from Analysts - Defense World

Feb 17, 2025
pulisher
Feb 16, 2025

Bicara Therapeutic, Inc. announced that it has received $108.234983 million in funding from a group of investors - Marketscreener.com

Feb 16, 2025
pulisher
Feb 16, 2025

Bicara Therapeutics (NASDAQ:BCAX) Receives Outperform Rating from Wedbush - MarketBeat

Feb 16, 2025
pulisher
Feb 15, 2025

Bicara Therapeutics (NASDAQ:BCAX) Stock Price Down 8.6%Here's Why - MarketBeat

Feb 15, 2025
pulisher
Feb 14, 2025

Bicara Therapeutics (NASDAQ:BCAX) Shares Up 7.3%Should You Buy? - MarketBeat

Feb 14, 2025
pulisher
Feb 14, 2025

Wedbush Reiterates Outperform Rating for Bicara Therapeutics (NASDAQ:BCAX) - Defense World

Feb 14, 2025
pulisher
Feb 11, 2025

Bicara Therapeutics Announces First Patients Enrolled in - GlobeNewswire

Feb 11, 2025
pulisher
Feb 11, 2025

Major Cancer Treatment Breakthrough? Phase 2/3 Trial Launches for Advanced Head & Neck Cancer - StockTitan

Feb 11, 2025
pulisher
Feb 11, 2025

Bicara Therapeutics (NASDAQ:BCAX) Upgraded to Strong-Buy at Wedbush - MarketBeat

Feb 11, 2025
pulisher
Feb 10, 2025

Bicara Therapeutics (BCAX) Projected to Post Quarterly Earnings on Tuesday - Defense World

Feb 10, 2025
pulisher
Feb 09, 2025

Bicara Therapeutics (NASDAQ:BCAX) Coverage Initiated at Wedbush - MarketBeat

Feb 09, 2025
pulisher
Feb 08, 2025

Wedbush Begins Coverage on Bicara Therapeutics (NASDAQ:BCAX) - Defense World

Feb 08, 2025
pulisher
Feb 07, 2025

Wedbush Upgrades Bicara Therapeutics (NASDAQ:BCAX) to “Strong-Buy” - Armenian Reporter

Feb 07, 2025
pulisher
Feb 07, 2025

Bicara Therapeutics (BCAX) to Release Earnings on Tuesday - MarketBeat

Feb 07, 2025
pulisher
Feb 06, 2025

Wedbush Initiates Coverage of Bicara Therapeutics (BCAX) with Outperform Recommendation - Nasdaq

Feb 06, 2025
pulisher
Feb 06, 2025

Wedbush Initiates Coverage on Bicara Therapeutics With Outperform, $31 Price Target - Marketscreener.com

Feb 06, 2025
pulisher
Feb 04, 2025

Bicara Therapeutics (NASDAQ:BCAX) Stock Price Up 9.7%Should You Buy? - MarketBeat

Feb 04, 2025
pulisher
Feb 03, 2025

Bicara reports positive Phase 1/1b trial results for cancer therapy - MSN

Feb 03, 2025
pulisher
Feb 02, 2025

Bicara Therapeutics: A Decline Off The IPO Spells 'Wait' For Me (NASDAQ:BCAX) - Seeking Alpha

Feb 02, 2025
pulisher
Jan 31, 2025

H.C. Wainwright lifts Bicara stock target to $45, maintains buy - MSN

Jan 31, 2025

Bicara Therapeutics Inc (BCAX) 재무 분석

Bicara Therapeutics Inc (BCAX)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
자본화:     |  볼륨(24시간):